Compare ADMA Biologics Inc (ADMA) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Upwork Inc — how do they compare? ADMA Biologics Inc trades at $9.92 (market cap $2.22B), while Upwork Inc trades at $8.23 (market cap $1.04B). The key difference: ADMA Biologics Inc is far larger — about 2.1× Upwork Inc's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | UPWK | |
|---|---|---|
Market Cap | $2.22B | $1.04B |
Sector | Health | Industrials |
52-Week High | $20.38 | $22.11 |
52-Week Low | $7.60 | $7.84 |
Enterprise Value | $2.29B | $806.15M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
UPWK trades at $9.83, up 1.65% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 EPS of $0.41, beating expectations, but revenue guidance disappointed investors, causing a recent stock decline. Fundamentals show solid profitability with a 12.93% net income margin and attractive valuation ratios, including a P/E of 10.71. Cash flow from operations remains strong at $248.26 million for 2025.
The outlook is mixed: strong fundamentals and analyst buy ratings support upside potential, but weak guidance and active client declines pose near-term risks. Investment opportunity lies in valuation appeal and AI integration, balanced by execution challenges in a competitive freelance market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
